|Bid||2.27 x 140400|
|Ask||2.33 x 135800|
|Day's Range||2.26 - 2.31|
|52 Week Range||1.87 - 4.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.10|
The biopharmaceutical company MOLOGEN AG presented two posters at the ESMO IO 2017 in Geneva, Switzerland .
The biopharmaceutical company MOLOGEN AG presented two sets of data on its lead compound, the immunotherapeutic agent lefitolimod, at the European Society for Medical Oncology in Madrid .
The biopharmaceutical company MOLOGEN AG announced today the signing of a binding term sheet that defines the framework for the collaboration between MOLOGEN and iPharma, a China-based drug development company.
The biopharmaceutical company MOLOGEN AG announced the key results of the extension phase of the exploratory phase Ib/IIa TEACH trial to evaluate lefitolimod in HIV-positive patients on antiretroviral therapy .
The biopharmaceutical company MOLOGEN AG has achieved the recruitment goal with the inclusion of currently 540 patients for the pivotal IMPALA study in metastatic colorectal cancer “mCRC”.
The biopharmaceutical company MOLOGEN AG announced the key results of the exploratory phase II IMPULSE study. The randomized study evaluated the efficacy and safety of lefitolimod in patients with extensive-disease small-cell lung cancer .
MOLOGEN AG had an eventful and positive fiscal year 2016. Almost all key milestones were reached in the last financial year.
The biotech company MOLOGEN AG announced today first combination data of its TLR9 agonists EnanDIM® with a checkpoint inhibitor.
The biotech company MOLOGEN AG announced today that its partner, the Danish Aarhus University Hospital, presented new data on the TEACH study at the annual Conference on Retroviruses and Opportunistic Infections in Seattle, USA.
Dr Matthias Baumann MD will join the Executive Board of biotechnology Company MOLOGEN AG as Chief Medical Officer on 1 May 2017.
The biotech company MOLOGEN AG announced today first combination data of its TLR9 agonist lefitolimod with checkpoint inhibitors.